Integrating next-generation sequencing into clinical practices: Sharing the real-world experiences
The NGS test has now become an important tool in precision medicine, and its use is also expanding in clinical practice. However, there are still issues about how to use it in the actual clinical field and in what direction in the clinical trials using it should be developed. In this session, opinions from outstanding experts from ASCO and KSMO will be heard on these issues.
Date & Time
Sep. 2 (Thu), 09:00-10:30
Venue
Room A
Chairs
Jin-Hyuk CHOI (KSMO President/ Ajou University Hospital, Korea)
Everett VOKES (ASCO President / University of Chicago Medicine, USA)
The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies, has changed the therapeutic landscape of some types of cancers. Despite some ICIs having manifested compelling clinical effectiveness in certain tumor types, the majority of patients still showed de novo or adaptive resistance. At present, the overall efficiency of immune checkpoint therapy remains unsatisfactory. This session will provide an opportunity to share the latest updates on new immunomodulating agents.
Date & Time
Sep. 2 (Thu), 09:00-10:30
Venue
Room B
Chairs
Dong-Wan KIM (Seoul National University Hospital, Korea)
Recently, immune checkpoint inhibitors including PD-1 inhibitors have become standard treatments in various types of cancers. Primary or acquired resistance has significantly developed in clinical practice, and these primary and acquired resistances have a negative effect on patients' treatment outcomes. Therefore, in this session, we will conduct a comprehensive overview of the primary and acquired resistances of immunotherapy and explore the mechanisms of resistance currently being presented. We will also look at the many efforts under way and explore strategies to overcome it.
Date & Time
Sep. 2 (Thu), 09:00-10:30
Venue
Room C
Chairs
Jin-Soo KIM (Seoul National Univerisity Boramae Medical Center, Korea)
Jedd D. Wolchok is leading melanoma and immunotherapy research at Memorial Sloan Kettering Cancer Center and is a professor of medicine at Weill Medical College of Cornell University. He led the introduction of immune checkpoint blockade to the oncology field and proposed Immune-Related Response Criteria (irRC) and Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST). At the forefront of cancer immunotherapy and as a clinician-scientist, his recent research is focused on overcoming treatment resistance and maximizing the efficacy of immunotherapy.
Scientific symposium 3 will cover the clinical application of circulating tumor DNA (ctDNA) profiles. This includes recent application machines, reagents, and quality control issues for ctDNA analysis. Also, this session will introduce the current status of ctDNA analysis in hospital settings and specialized companies for genetic analysis in Korea. The final part will be presented as clinical application of ctDNA profiles in the perspective of the US.
Endocrine therapy in oncology is one of the oldest targeted therapies. In particular, endocrine therapy in breast and prostate cancer is still used as the most potent anti-tumor therapy. Moreover, the recent development of new drugs to overcome endocrine resistance has had a powerful effect on survival improvement. In this session, the development of endocrine therapy in breast and prostate cancer will be reviewed, and future treatment directions will be discussed.
Date & Time
Sep. 2 (Thu), 12:40-14:10
Venue
Room B
Chairs
Kyong Hwa PARK (Korea University Anam Hospital, Korea)
Immunotherapy has shown remarkable advances in metastatic gastric cancer and recently acquired a new FDA indication for the first-line therapy. In the anti-HER2 targeted therapy, novel game-changers are emerging one after another, and the combined effect of immunotherapy and anti-HER2 targeted therapy is also attracting significant attention.
This session talks about the latest knowledge and future development direction of immunotherapy and anti-HER2 targeted therapy in gastric cancer. In addition, an exciting talk has been prepared about GIST, which recently received approval by the FDA for the new 4th-line therapy.
Date & Time
Sep. 2 (Thu), 14:30-15:30
Venue
Room A
Chairs
Yoon-Koo KANG (Asan Medical Center, Korea)
Kohei SHITARA (National Cancer Center Hospital East, Japan)
Conducting phase I clinical trial with targeted therapy/immunotherapy
Clinical research in the oncologic field has been expanding and changing in recent years. In particular, early-stage oncologic clinical trials are conducted with precision medicine and immune-oncologic drugs under a multidisciplinary approach, moving away from the traditional approach that used only cytotoxic anticancer drugs. This session will discuss the changes and experiences in these early-stage oncology clinical trials.
Date & Time
Sep. 2 (Thu), 14:30-15:30
Venue
Room C
Chairs
Dae Young ZANG (Hallym University Sacred Heart Hospital, Korea)
Tae-Yong KIM (Seoul National University Hospital, Korea)
Dong-Hoe KOO (Kangbuk Samsung Hospital, Korea)
Presentation Detail
1.Eribulin synergizes abemaciclib in Palbociclib-resistant breast cancer model by inhibiting G2/M phase of cell cycle Yong Wha MOON (CHA Bundang Medical Center, Korea)
2.Development of PTEN alteration driven targeted chemotherapy with caspase-3 cleavable peptide-drug conjugate to treat metastatic triple-negative breast cancer Young Seok CHO (Seoul National University, Korea)
3.On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study with immune correlates Chang Gon KIM (Yonsei Cancer Center, Korea)
4.Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis Jae Sik KIM (Seoul National University, Korea)
5.Adjuvant radiotherapy versus surveillance for grade 2 intracranial meningiomas: A multicenter study Hwa Kyung BYUN (Yonsei Cancer Center, Korea)
6.Evaluation of Pembrolizumab monotherapy in patients with salivary gland carcinoma in the phase 2 KEYNOTE-158 study Do-Youn OH (Seoul National University Hospital, Korea)
This session will be a time to share strategies for successful biomarker-based clinical trials. In particular, advice from experts in each country on networking and logistics will be covered, which are important for conducting actual biomarker-based clinical trials.
Date & Time
Sep. 2 (Thu), 15:50-17:20
Venue
Room A
Chairs
Sun Young RHA (Yonsei Cancer Center, Korea)
Akinobu HAMADA (National Cancer Center Research Institute, Japan)
Updates of IO treatments and Asian subgroup analysis in oncology clinical trials
In this session, we will cover the latest insights in immuno-cancer treatments that have been successfully used alone or in combination in several settings. It will also cover the implications of individual analyses of Asian races in multinational clinical trials.
Date & Time
Sep. 2 (Thu), 15:50-17:20
Venue
Room B
Chairs
Tae Won KIM (Chairman, Board of Directors of KSMO, Asan Medical Center, Korea)
Nicolas GIRARD (ESMO Officer, Institute Curie, France)
Scientific session 5 will deal with the latest knowledge and advances in the field of non-small cell lung cancer and small cell lung cancer. Targeted agents for EGFR mutation and ALK rearrangement, which are representative anti-cancer targets in solid tumors, are leading the development of targeted therapeutics, and a competition between existing drugs and new drugs is taking place. We would like to share with international leaders the latest knowledge and the best treatment strategies.
The treatment of small cell lung cancer had shown slow development for decades. The introduction of immune-check point inhibitors has laid the foundation for a leap forward. The attempt to newly classify small cell lung cancer can also be said to be a preparation for the future leap forward. The presentation of researchers representing Germany are anticipated.
Date & Time
Sep. 2 (Thu), 15:50-17:20
Venue
Room C
Chairs
Dong-Wan KIM (Seoul National University Hospital, Korea)
Martin SEBASTIAN (University Hospital Frankfurt, Germany)
Giuseppe Curigliano, is an associate professor of medical oncology at the University of Milano and head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy. He is a renowned researcher specializing in early drug development and breast cancer clinician. He is also serving as a chair, organizer, and faculty member in various meetings in the oncology and breast cancer field.
Recently, he went through and overcame the COVID-19 pandemic in Northern Italy and proposed guidelines for continuing care and research for cancer patients. As a plenary speaker, he will share his insights and vision for patient care and research in the pandemic era.
